Literature DB >> 3047614

Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses.

N J Finkler1, B Benacerraf, P T Lavin, C Wojciechowski, R C Knapp.   

Abstract

The ability to differentiate a malignant from a benign ovarian mass was assessed for four diagnostic procedures: serum CA 125, clinical examination, original ultrasound, and reviewer ultrasound interpretation. When these tests were used individually, the sensitivity and specificity of CA 125 levels were equal to those of a review ultrasound. Overall, the sensitivity of clinical impression and original ultrasound was poor. Sensitivity and specificity were highest for CA 125 assays in postmenopausal patients, especially when these were used as the second diagnostic test. Positive and negative predictive values significantly increased among postmenopausal patients when CA 125 was added to any of the other diagnostic tests examined. In conjunction with such tests, measurement of serum CA 125 significantly increased diagnostic accuracy and may thus have an important role in the preoperative evaluation of women with ovarian masses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3047614

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

Review 1.  Management of gynaecological cancers.

Authors:  A Melville; A Eastwood; J Kleijnen; H Kitchener; P Martin-Hirsch; L Nelson
Journal:  Qual Health Care       Date:  1999-12

2.  Ovarian cancer screening.

Authors:  C I Macri; P J DiSaia
Journal:  West J Med       Date:  1992-06

3.  Management of ovarian cysts.

Authors:  J Salat-Baroux; P Merviel; F Kuttenn
Journal:  BMJ       Date:  1996-11-02

4.  Laparoscopic Management of Adnexal Masses.

Authors:  B S Duggal; P Tarneja; R K Sharma; S K Rath; R D Wadhwa
Journal:  Med J Armed Forces India       Date:  2011-07-21

5.  Management of a suspicious adnexal mass: a clinical practice guideline.

Authors:  J E Dodge; A L Covens; C Lacchetti; L M Elit; T Le; M Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

6.  Comparison of four malignancy risk indices in the detection of malignant ovarian masses.

Authors:  Erhan Aktürk; Rıza Efendi Karaca; Ibrahim Alanbay; Murat Dede; Emre Karaşahin; Müfit Cemal Yenen; Iskender Başer
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401

7.  Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.

Authors:  L A Cole; J H Nam
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

8.  Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.

Authors:  O Mogensen; B Mogensen; A Jakobsen
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

9.  The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.

Authors:  Kyung Hee Han; Noh Hyun Park; Jin Ju Kim; Sunmie Kim; Hee Seung Kim; Maria Lee; Yong Sang Song
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.